首页> 美国卫生研究院文献>Neuro-Oncology >ACTR-74. A PHASE IB/II OPEN-LABEL MULTICENTER STUDY OF CAPMATINIB (INC280) ALONE AND IN COMBINATION WITH BUPARLISIB (BKM120) IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA

【2h】

ACTR-74. A PHASE IB/II OPEN-LABEL MULTICENTER STUDY OF CAPMATINIB (INC280) ALONE AND IN COMBINATION WITH BUPARLISIB (BKM120) IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA

机译：ACTR-74。复发性胶质母细胞瘤成年患者中单用卡马替尼（INC280）联合布巴利单抗（BKM120）进行的IB / II期开放式多中心研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BACKGROUNDc-MET and PI3K pathways are dysregulated in GBM and can drive cancer growth in pre-clinical models. INC280 is a small molecule inhibitor of c-MET; BKM120 is a pan-class I PI3K inhibitor. A phase Ib/II study was designed to evaluate INC280+BKM120 in patients with recurrent GBM ().

机译：背景技术GBM中的c-MET和PI3K通路失调，可在临床前模型中推动癌症的生长。 INC280是c-MET的小分子抑制剂； BKM120是一种泛I类PI3K抑制剂。 Ib / II期研究旨在评估复发性GBM患者的INC280 + BKM120（）。

著录项

期刊名称 Neuro-Oncology
作者
Martin van den Bent; Analia Azaro; Filip Vos; Juan Sepulveda; W K Alfred Yung; Patrick Wen; Andrew Lassman; Markus Joerger; Ghazaleh Tabatabai; Jordi Rodon; Ralph Tiedt; Sylvia Zhao; Tiina Kirsilae; Sergio Vicente; Andrea Myers; Wolfgang Wick;
展开▼
作者单位

展开▼
年(卷),期 2017(19),Suppl 6
年度 2017
页码 vi16–vi17
总页数 2
原文格式 PDF
正文语种
中图分类神经病学;肿瘤学;
关键词
入库时间 2022-08-17 12:25:43

相似文献

外文文献

1. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial [J] . Wen Patrick Y., Touat Mehdi, Alexander Brian M., Journal of Clinical Oncology . 2019,第9期

机译：患有磷脂酰肌醇3-激酶途径的患者患者的Buparlisib：开放标签，多中心，多臂，II期试验
2. An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer [J] . Waller Cornelius F., Vynnychenko Ihor, Bondarenko Igor, Clinical lung cancer . 2015,第2期

机译：甲磺酸依瑞布林联合培美曲塞和单独使用培美曲塞作为二线治疗在晚期非鳞状非小细胞肺癌患者中的开放标签，多中心，随机Ib / II期研究
3. MEVITEM: A EUROPEAN, RANDOMIZED, OPEN-LABEL PHASE I/II STUDY OF VISMODEGIB IN COMBINATION WITH TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN ADULT PATIENTS WITH RECURRENT OR REFRACTORY MEDULLOBLASTOMA PRESENTING AN ACTIVATION OF THE SONIC HEDGEHOG PATHWAY [J] . Frappaz D., Meyronnet D., Garin G., Neuro-Oncology . 2016,第suppla4期

机译：方案：欧洲，无规，开放性I / II期研究，在具有复发性或难治性髓母细胞瘤的成年患者中，将维莫昔单抗与替莫唑胺与替莫唑胺联合用于成年或难治性髓母细胞瘤。
4. PHASE II OPEN-LABEL STUDY OF SINGLE-AGENT HYDROXYUREA FOR TREATMENT OF ADVANCED CUTANEOUS MAST CELL TUMORS IN DOGS [C] . Ken Rassnick, Renee Al-Sarraf, Dennis Bailey, Annual Conference of the Veterinary Cancer Society . 2009

机译：单药羟基脲的第II期开放标签研究，用于治疗犬晚皮腰肿瘤瘤
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. ATNT-12PHASE I TWO-STAGE OPEN-LABEL DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) [O] . Jordi Rodon, Mark Rosenthal, Warren Mason, 2015

机译：新诊断的胶质母细胞瘤（GBM）患者中BUPARLISIB（BKM120）与辅助性替莫唑胺（TMZ）联合放疗（RT）和TMZ联合进行的ATNT-12阶段一期两阶段开放剂量剂量研究
7. A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma [O] . Martin van den Bent, Analia Azaro, Filip De Vos, 2019

机译：单独的IB / II，Open-Label，Inc280（Capmatinib）的多中心研究单独，并与成年患者复发胶质母细胞瘤的Buparlisib（BKM120）组合

ACTR-74. A PHASE IB/II OPEN-LABEL MULTICENTER STUDY OF CAPMATINIB (INC280) ALONE AND IN COMBINATION WITH BUPARLISIB (BKM120) IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA

摘要

著录项

相似文献

相关主题

期刊订阅